CareSet supercharges pharma marketing initiatives as the first company commercializing 100% of Medicare A, B, C and D claims

DocGraph Hop Teaming Data Set Released at Datapalooza

CareSet Labs released the DocGraph Hop teaming data set during Datapalooza 2018. This data set is one of the most detailed and current picture of the patient-sharing relationships between providers in the US healthcare system.

CareSet at SXSW 2018 "Put down the Scalpel: Non Invasive Heart Solutions"

New school medical diagnostics and interventions aim to reduce unnecessary procedures, saving cost and time, and allowing innovators to shine.

Inflectra Launch: A Medicare Data Perspective

How biosimilars are grabbing market share, and how Medicare data provides an unfair advantage.

This case study explores how you can bring your market into laser focus with CareSet Target and aim your sales force where your product is most needed.

CareSet Target: Outpatient Therapy Volumes Case Study

Knowing the scale of your market and the trends that point to opportunities for your product is what CareSet Journey is all about. This case study looks at trends in cancer patient readmissions and points to where those trends are most pronounced.

CareSet Journey: Readmission Case Study

Immuno-oncology 101

In March 2011, the FDA approved a little molecule called Ipilimumab, better known as Yervoy. Learn why we think Yervoy’s approval marked the dawn of the immuno-oncology age.

DocGraph Hop Teaming Data Set Released at Datapalooza

CareSet at SXSW 2018 "Put down the Scalpel: Non Invasive Heart Solutions"

New school medical diagnostics and interventions aim to reduce unnecessary procedures, saving cost and time, and allowing innovators to shine.

Inflectra Launch: A Medicare Data Perspective - copy

Inflectra Launch: A Medicare Data Perspective

How biosimilars are grabbing market share, and how Medicare data provides an unfair advantage.

CareSet Target: Outpatient Therapy Volumes Case Study

This case study explores how you can bring your market into laser focus with CareSet Target and aim your sales force where your product is most needed.

CareSet Journey: Readmission Case Study

Immuno-oncology 101

In March 2011, the FDA approved a little molecule called Ipilimumab, better known as Yervoy. Learn why we think Yervoy’s approval marked the dawn of the immuno-oncology age.

Target your market quickly and efficiently.

USING THE LARGEST SINGLE COHORT OF PATIENTS AVAILABLE, CareSet groups Medicare claims into patient journeys by disease. We then track how their diseases progress and which teams of doctors treat them.

For outcomes research teams, understanding disease progression creates new patient segmentation. For brand managers, knowing which practices to talk to enables more targeted outreach in less time.

Learn About Our Products

CareSet in Action

A large pharma company wanted to better understand disease progression for patients with an age-related illness, and worked with CareSet and another claims vendor to track comorbidities, procedures, and other claims-related events both prior to and after diagnosis date. Our work resulted in a change to the overall design study and better quality data for the outcomes research group.

Examine claims data with freedom

Patch software gives you the power to find and analyze information using your own parameters. We provide fresh, rich data – you view it like never before

4,763,890

Provider & Organizational Records

$448,308,454,852

Annual Claims

50,230,559

Beneficiaries Covered